 treatment tuberculosi patient advanc human immunodefici viru infect background and method infect human immunodefici viru hiv risk tuberculosi effect antituberculosi chemotherapi outcom patient diagnos retrospect studi patient immunodefici syndrom aid tuberculosi case registri san francisco result time diagnosi tuberculosi patient percent diagnosi aid patient percent concomit diagnosi aid presenc aids-defin diseas tuberculosi patient percent aid manifest tuberculosi pulmonari patient percent extrapulmonari patient percent pulmonari extrapulmonari patient percent treatment regimen isoniazid rifampin ethambutol first month patient isoniazid rifampin pyrazinamid ethambutol first month patient isoniazid rifampin patient isoniazid rifampin pyrazinamid first month patient drug regimen patient intend durat treatment patient regimen pyrazinamid month patient pyrazinamid month seven patient treatment tuberculosi death sputum clear acid-fast organ median week therapi abnorm radiograph month treatment stabl patient new nontubercul infect treatment failur man multipl drug-resist organ therapi advers drug reaction patient percent patient median surviv month diagnosi tuberculosi tuberculosi major contributor death untreat patient patient patient therapi relaps percent complianc poor conclus tuberculosi substanti mortal patient advanc hiv infect patient regimen convent therapi result rapid steril sputum radiograph improv low rate relaps